Performance characteristics and patient comparison of the ARK Diagnostics levetiracetam immunoassay with an ultra-high performance liquid chromatography with tandem mass spectrometry detection method

Clinica Chimica Acta

Volumn 413, Issue 3-4, 2012, Pages 529-531

  Juenke, JoEtta M ^a   McGraw, J Paul ^a   McMillin, Gwendolyn A ^a,b   Johnson Davis, Kamisha L ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE;

DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; ENZYME ACTIVITY; EPILEPSY; HUMAN; IMMUNOASSAY; LETTER; PRIORITY JOURNAL; SPECTROPHOTOMETRY; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOASSAY; PIRACETAM; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84355163125     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.11.018     Document Type: Letter

References (22)

1. Leppik I.E. The place of levetiracetam in the treatment of epilepsy. Epilepsia 2001, 42:S44-S45.
2. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004, 43:707-724.
3. Ben-Menachem E., Edrich P., Van Vleymen B., Sander J.W., Schmidt B. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 2003, 53(1-2):57-64.
4. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol Jun 2003, 2(6):347-356.
5. Johannessen S.I., Battino D., Berry D.J., et al. Therapeutic drug monitoring of the newer antiseizure drugs. Ther Drug Monit 2003, 25:347-363.
6. Lamberty Y., Gower A.J., Klitgaard H. The new antiseizure drug levetiracetam normalizes chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol 2002, 439(1-3):101-106.
7. Frucht S.J., Louis E.D., Chuang C., Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001, 57(6):1112-1114.
8. Krauss G.L., Bergin A., Kramer R.E., Cho Y.W., Reich S.G. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001, 56(3):411-412.
9. Barrueto f., Williams K., Howland M.A., Hoffman R.S., Nelson L.S. A case of levetiracetam poisoning with clinical and toxicokinetic data. J Toxicol Clin Toxicol 2002, 40(7):881-884.
10. Alsaadi T.M., Thieman C. Levetiracetam monotherapy for newly diagnosed epilepsy patients. Seizure 2003, 12(3):154-156.
11. Farooq M.I.J., Bhatt A., Majid A., Gupta R., Khasnis A., Kassab M.Y. Levetiracetam for managing neurological and psychiatric disorders. Am J Health Syst Pharm 2009, 66(6):541-561.
12. Guay D.R. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother Sep 2003, 1(1):18-37.
13. Nau K.M., Divertie G.D., Valentino A.K., Freeman W.D. Saftey and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care 2009, 11:34-37.
14. Lacerda G., Krummel T., Sabourdy C., Ryvlin P., Hirsch E. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology Dec 26 2006, 67:S28-S33.
15. Lopez-Fraile I.P., Cid A.O., Juste A.O., Modrego P.J. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy Behav Jul 2009, 15(3):372-375.
16. Lins R.L., Otoul C., De Smedt F., Coupez R., Stockis A. Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. Int J Clin Pharmacol Ther 2007, 45:47-54.
17. Grim S.A., Ryan M., Miles M.V., et al. Correlation of levetiracetam concentrations between serum and plasma. Ther Drug Monit 2003, 25:61-66.
18. Patsalos P.N., Ghattaura S., Ratnaraj N., Sander J.W. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia Nov 2006, 47(11):1818-1821.
19. Juenke J.M., Brown P.I., Urry F.M., McMillin G.A. A procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. J Anal Toxicol Jan/Feb 2006, 30(1):27-30.
20. Blonk M.I., van der Nagel B.C., Smit L.S., Mathot R.A. Quantification of levetiracetam in plasma of neonates by ultra-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878(7-8):675-681.
21. Greiner-Sosanko E., Giannoutsos S., Lower D.R., Virji M.A., Krasowski M.D. Drug monitoring: simultaneous analysis of lamotrigine, oxcarbazepine, 10-hydroxycarbazepine, and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetam. J Chromatogr Sci 2007, 45(9):616-622.
22. Juenke J.M., Brown P.I., Johnson-Davis K.L., McMillin G.A. Simultaneous quantification of levetiracetam and gabapentin in plasma by ultrahigh-pressure liquid chromatography with tandem mass spectrometric detection. Ther Drug Monit TDM 2011, Apr;33(2):209-13.